Skip to main navigation Skip to search Skip to main content

Recent advances in cancer therapy-associated oral mucositis

  • Ragda Abdalla-Aslan
  • , Rebeca Keegan
  • , Yehuda Zadik
  • , Noam Yarom
  • , Sharon Elad*
  • *Corresponding author for this work

    Research output: Contribution to journalReview articlepeer-review

    9 Scopus citations

    Abstract

    Oral mucositis (OM) is a common and debilitating toxicity of cancer treatments – chemotherapy, radiotherapy, hematopoietic cell transplant, or combinations. OM is associated with severe oral pain and has negative impacts on patient function and quality of life. Additionally, OM has accompanying systemic complications that may have critical implications. These local and systemic consequences can alter cancer treatment, and add an economic burden. This review covers the clinical presentation and course of OM, differential diagnosis, clinical and economic impacts, pathogenesis, risk factors, assessment measures, biomarkers and prediction of OM, management, research advances in the development of new drugs and treatments, and big data.

    Original languageEnglish
    Pages (from-to)2695-2710
    Number of pages16
    JournalOral Diseases
    Volume31
    Issue number9
    DOIs
    StatePublished - Sep 2025

    Bibliographical note

    Publisher Copyright:
    © 2024 Wiley Periodicals LLC.

    UN SDGs

    This output contributes to the following UN Sustainable Development Goals (SDGs)

    1. SDG 3 - Good Health and Well-being
      SDG 3 Good Health and Well-being

    Keywords

    • cancer
    • chemotherapy
    • hematopoietic stem cell transplantation
    • mucosal injury
    • oral mucositis
    • radiotherapy

    Fingerprint

    Dive into the research topics of 'Recent advances in cancer therapy-associated oral mucositis'. Together they form a unique fingerprint.

    Cite this